In support of countries for now neglected by the distribution of vaccines, Novavax's NVX-CoV2373 should arrive in September and will require authorizations all over the world.
Very early a new vaccine against the coronavirus will be added to the list of those approved internationally, and it is the American Novavax which for the moment has made it known that the experimental results have also given positive results on the variants with the 90% coverage.In September it could apply for approval for emergency use from the US drug regulator, the FDA, the European EMA and other countries.
The study was conducted on 29,960 people and the vaccine demonstrated an efficacy of 90.4%.
Novavax will initially be able to make it available to the international community 100 million doses of vaccine.
Novavax's third way: protein-based vaccine
Novavax brings a novelty in terms of pharmaceutical techniques and technologies used in the fight against the coronavirus. The pharmaceutical company has in fact opted for a protein-based vaccine, which contains tiny particles obtained from a laboratory-produced version of the Spike protein present on the surface of the pandemic coronavirus.
The vaccine also uses an adjuvant (Matrix-M1), which is a substance that helps strengthen the immune responses stimulated by the vaccine.
Where will the NVX-CoV2373 vaccine go
The French vaccine
The European Commission is also in talks with the French company Valneva with which, however, no contract has yet been signed for any 30 million doses.
| Title | Topics | Year | Links | Document | Notes |
|---|---|---|---|---|---|
| Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the US and Mexico | COVID-19 | 2020 | Downloads | Updated May 10, 2021 | |
| Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the UK | COVID-19 | 2020 | Downloads | Updated April 5, 2021 | |
| Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa | COVID-19 | 2020 | Downloads | Updated January 25, 2021 |
Note:
NVX-CoV 7 is a vaccine designed to provide protection against COVID-19. Designed from the genetic sequence of COVID-19, recombinant nanoparticle technology was used to generate antigens derived from the spike protein of the coronavirus. In combination with the proprietary adjuvant Matrix-M™, NVX-CoV 7 has been shown in preclinical studies to bind efficiently with human receptors targeted by the virus, critical for effective vaccine protection.
Novavax's proprietary saponin-based Matrix-M™ adjuvant demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells to the injection site and improving antigen presentation in local lymph nodes, increasing the immune response. In particular Matrix-M is composed of 40 nanometric particles based on saponin extracted from the bark of Quillaja saponaria Molina together with cholesterol and phospholipids.
Novavax is a US company operating in the field of biotechnology. Founded in 1987, it is headquartered in Gaithersburg, Maryland: it was included in the Russell 2000 Index and is listed on the Nasdaq.
The company is primarily engaged in vaccine development and has facilities in Rockville, Maryland, and Uppsala, Sweden. His research has never produced any vaccine that has come on the market. Starting in 2020, the study and development of a vaccine against SARS-CoV-2, the virus responsible for the COVID-19 pandemic, began. This vaccine, called NVX-CoV2373, reached Phase III of development in January 2021.
